Clear Cell Renal Cell Carcinoma — the renal-oncology intersection — is the most actionable rare-cancer cross-tag in the AimwellBio Federated Intelligence Network. ccRCC sits at a price-and-policy convergence: the HIF-2α inhibitor class (Welireg), the cabozantinib-nivolumab combination standard, and the next-line TKI repositioning are all in active rewrite through 2025–2026. AimwellBio operates a dedicated ccRCC corpus — 421 high-confidence source-cited signals built from a focused CT.gov + PubMed + SEC EDGAR ingest scoped to clear-cell renal terminology, then post-process filtered to drop drug-name false positives where the trial was not actually for RCC.
ccRCC is the proving ground for two of the highest-cost frontier mechanisms in oncology. Welireg (belzutifan) opened the HIF-2α inhibitor class with a renal-first label. Cabometyx + Opdivo and Sutent / Inlyta sit on the immuno-oncology + tyrosine kinase inhibitor combination standard. Reimbursement decisions on combination pricing, label expansion, and next-line repositioning across 2025–2026 will reset the entire renal-oncology spend curve.
Clear-cell renal cell carcinoma is rare in absolute incidence but disproportionately represented in the patient panels of GCC sovereign cancer institutions. King Faisal Specialist Hospital, Cleveland Clinic Abu Dhabi, King Hussein Cancer Center, 57357 Cairo, and Hamad Medical Corporation anchor the regional demand vector for high-cost ccRCC therapy access. Vision 2030 oncology procurement cycles read against the dedicated ccRCC corpus, not generalized oncology coverage.
ccRCC is structurally a cross-tag — every signal lives in the renal corpus and the oncology corpus simultaneously. AimwellBio resolves the duplication by maintaining a dedicated 421-signal authoritative ccRCC corpus and exposing the 19 cross-tagged signals from the underlying renal and oncology feeds as natural overlaps. Provenance, source method, and confidence on every signal. No hallucination tolerance for ministry-scale procurement.
Built from a focused ingest of ClinicalTrials.gov + PubMed + SEC EDGAR queries scoped to clear-cell renal cell carcinoma terminology, then filtered post-process to drop drug-name false positives where the trial wasn't actually for RCC. 1,032 raw signals → 421 high-confidence retained (40.8% retention).
Peer-reviewed ccRCC literature: HIF-2α biology, IO+TKI combination outcomes, MRD and ctDNA in RCC, real-world survival data.
10-Q, 10-K, and 8-K filings from the 31 RCC-focused entities. Pipeline disclosure, royalty terms, and indication-expansion language.
Active and recently completed ccRCC interventional trials. Phase 2 / Phase 3 readouts, sponsor-flagged combo studies, sovereign-region site enrollment.
1,032 raw signals → 421 retained after drug-name false-positive filtering. The retention discipline is the cited methodology.
Each entity is mapped into AIMN:ATLAS with continuous SEC, ClinicalTrials.gov, and PubMed coverage. Five sovereign-anchored institutions across KSA / GCC / MENA are flagged. Click any name to open its company dossier.
Clear-cell renal cell carcinoma is rare in incidence but disproportionately surfaces inside the patient panels of the largest GCC and MENA cancer institutions. AimwellBio's ccRCC corpus is read against the regional demand vector each of these institutions creates. Vision 2030 ministry-procurement cycles for HIF-2α inhibitors and IO+TKI combinations close inside windows measured in months.
ccRCC lives at the intersection of two upstream feeds — renal and oncology. Most pipelines treat the overlap as a tag and stop there. AimwellBio resolves it as a first-class corpus with its own ingest, its own filter discipline, and its own 421-signal authoritative dataset.